Pharma Outlook 2025
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
Pharma
“Access to Talent is a Crucial Factor”
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
Hovione and Firstgene Announce Strategic Collaboration
Exclusive licensing and R&D collaboration between Hovione and Firstgene.
PCI Pharma Services Acquires Ajinomoto Althea
PCI Pharma Services has completed its acquisition of Ajinomoto Althea, a CDMO subsidiary of Ajinomoto.
Roquette Acquires IFF Pharma, Reorganizes into Two Business Groups
Roquette completes IFF Pharma Solutions acquisition and unveils new structure for global growth and innovation.
Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics
MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.
Austria: A Hotspot for Life Sciences
An Attractive and Highly Sought-after Business Location
The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.
Insights into Biologics and Pharmaceutical Manufacturing
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
Increasing Gap in Biotech Venture Funding
Consulting firm BCG has evaluated the effectiveness of biotech innovation centers in Europe and the USA. Adolphs explains what is lacking in Germany in particular.
Europe’s Biotech Cluster Powerhouses
Cambridge, Leiden, Heidelberg or Paris - many European countries have biotechnology clusters in which scientific expertise meets a well-developed infrastructure, committed entrepreneurship and attractive financing opportunities. A subjective look at the best.
Productivity in Biopharma Research Picks Up
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
The Success Story of Biosimilars
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
Expanding Expertise in Highly-Potent APIs
After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.
Small Substances with Big Effects
The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.
